Literature DB >> 11169433

Anti-inflammatory activity of nerve growth factor in experimental autoimmune encephalomyelitis: inhibition of monocyte transendothelial migration.

A Flügel1, K Matsumuro, H Neumann, W E Klinkert, R Birnbacher, H Lassmann, U Otten, H Wekerle.   

Abstract

In order to analyze a putative immunomodulatory effect of NGF in experimental autoimmune encephalomyelitis (EAE) of the Lewis rat, we transduced myelin basic protein (MBP)-specific CD4(+) T cells with a recombinant retrovirus encoding NGF. These T(MBP)NGF cells secreted high levels of NGF, along with an unaltered Th1-like cytokine pattern. Transfer studies showed that T(MBP)NGF cells were unable to mediate clinical EAE, when transferred alone, and, more important, they efficiently suppressed induction of clinical EAE by non-transduced MBP-specific T cells (T(MBP )cells). In contrast, NGF transduced ovalbumin-specific T cells, which secreted high NGF levels, did not affect EAE induction. Suppression of clinical EAE by T(MBP)NGF cells was associated with a general reduction of inflammatory CNS infiltrates, with a most pronounced decrease of the monocyte/macrophage component. Using a culture model of the endothelial blood-brain barrier (BBB), we found that NGF directly acts on blood-derived monocytes via the p75 NGF receptor, thus interfering with monocyte migration through the activated BBB endothelium. Our data establish NGF as an anti-inflammatory mediator interfering with T cell mediated autoimmune disease in the CNS. They further point to monocyte migration through blood vascular endothelium as one possible mechanism of NGF action.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11169433     DOI: 10.1002/1521-4141(200101)31:1<11::AID-IMMU11>3.0.CO;2-G

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  25 in total

Review 1.  Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.

Authors:  Reinhard Hohlfeld; Hartmut Wekerle
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-11       Impact factor: 11.205

Review 2.  Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis.

Authors:  Tjalf Ziemssen
Journal:  J Neurol       Date:  2005-11       Impact factor: 4.849

Review 3.  The neuroprotective role of inflammation in nervous system injuries.

Authors:  Jorge Correale; Andrés Villa
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

4.  Neuroprotection by ulinastatin in experimental autoimmune encephalomyelitis.

Authors:  Yaqing Shu; Yu Yang; Wei Qiu; Zhengqi Lu; Ying Li; Jian Bao; Ming Feng; Xueqiang Hu
Journal:  Neurochem Res       Date:  2011-06-12       Impact factor: 3.996

Review 5.  The mechanism of action of interferon-β in relapsing multiple sclerosis.

Authors:  Bernd C Kieseier
Journal:  CNS Drugs       Date:  2011-06-01       Impact factor: 5.749

Review 6.  Gene Therapy for Autoimmune Disease.

Authors:  Shang-An Shu; Jinjun Wang; Mi-Hua Tao; Patrick S C Leung
Journal:  Clin Rev Allergy Immunol       Date:  2015-10       Impact factor: 8.667

7.  Live Lactobacillus rhamnosus [corrected] is essential for the inhibitory effect on tumor necrosis factor alpha-induced interleukin-8 expression.

Authors:  Donglai Ma; Paul Forsythe; John Bienenstock
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

8.  Significance of Conversation between Mast Cells and Nerves.

Authors:  Hanneke Pm van der Kleij; John Bienenstock
Journal:  Allergy Asthma Clin Immunol       Date:  2005-06-15       Impact factor: 3.406

9.  Astrocytes protect the CNS: antigen-specific T helper cell responses are inhibited by astrocyte-induced upregulation of CTLA-4 (CD152).

Authors:  Ulrike Gimsa; Anita ØRen; Pushpa Pandiyan; Daniela Teichmann; Ingo Bechmann; Robert Nitsch; Monika C Brunner-Weinzierl
Journal:  J Mol Med (Berl)       Date:  2004-03-09       Impact factor: 4.599

Review 10.  Molecular pathogenesis of neuroinflammation.

Authors:  M Bradl; R Hohlfeld
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-10       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.